L-Carnitine Supplementation in Patients with Advanced Cancer and Carnitine Deficiency

A Double-Blind, Placebo-Controlled Study

Ricardo A. Cruciani, Ella Dvorkin, Peter Homel, Bruce Culliney, Stephen Malamud, Jeanne Lapin, Russell K. Portenoy, Nora Esteban-Cruciani

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Carnitine deficiency is prevalent in populations with chronic illness, including cancer. In a recent open-label study, L-carnitine supplementation was well tolerated and appeared to improve fatigue and other outcomes in cancer patients. To further evaluate this finding, adult patients with advanced cancer, carnitine deficiency (free carnitine more than 35 μmol/L for males or less than 25 μmol/L for females, or acyl/free carnitine ratio of more than 0.4), moderate to severe fatigue, and a Karnofsky Performance Status (KPS) score of 50 or more, were randomly assigned to receive either L-carnitine (0.5 g/day for two days, followed by 1 g/day for two days, and then 2 g/day for 10 days) or placebo. This double-blind phase was followed by an open-label phase, during which all patients received L-carnitine supplementation for two weeks. Outcomes included the fatigue subscale of the Functional Assessment of Cancer Therapy-Anemia (FACT-An), the Linear Analog Scale Assessments (LASA), the Mini-Mental State Exam (MMSE), and the KPS. Twenty-nine patients (12 placebo, 17 L-carnitine) were included in the intent-to-treat (ITT) analysis. From baseline to the end of the double-blind phase, serum total and free L-carnitine increased from 32.9 ± 3.8 to 56.6 ± 20.5 (P = 0.004), and from 22.9 ± 19.4 to 45.3 ± 17.2 (P = 0.004), respectively, in the L-carnitine-treated group, and from 28.2 ± 10.2 to 36.2 ± 8.7 (P = ns), and from 22.6 ± 7.9 to 28.7 ± 8.6 (P = ns) in the placebo group, respectively. The planned ITT analysis revealed no significant improvement in any of the study's endpoints, and these negative findings were not different when data from two patients who did not adhere to the protocol were eliminated. However, an exploratory covariate analysis that excluded these two protocol violators and included outcome data from both the double-blind and open-label phases demonstrated significantly improved fatigue on the FACT-An fatigue subscale (P < 0.03), and significantly improved FACT-An functional well-being subscale (P < 0.03), and KPS (P < 0.003), in the group that started with L-carnitine during the double-blind phase. These data do not support the conclusion that L-carnitine in the doses tested reverses cancer-related fatigue in carnitine-deficient patients. However, L-carnitine supplementation does increase L-carnitine serum levels, and the positive findings in an exploratory analysis justify a larger study to determine if this strategy could be of benefit for a subpopulation of cancer patients.

Original languageEnglish (US)
Pages (from-to)622-631
Number of pages10
JournalJournal of Pain and Symptom Management
Volume37
Issue number4
DOIs
StatePublished - Apr 2009

Fingerprint

Carnitine
Placebos
Neoplasms
Fatigue
Karnofsky Performance Status
Anemia
Serum

Keywords

  • advanced cancer
  • carnitine deficiency
  • L-Carnitine
  • supplementation

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine
  • Clinical Neurology
  • Nursing(all)

Cite this

L-Carnitine Supplementation in Patients with Advanced Cancer and Carnitine Deficiency : A Double-Blind, Placebo-Controlled Study. / Cruciani, Ricardo A.; Dvorkin, Ella; Homel, Peter; Culliney, Bruce; Malamud, Stephen; Lapin, Jeanne; Portenoy, Russell K.; Esteban-Cruciani, Nora.

In: Journal of Pain and Symptom Management, Vol. 37, No. 4, 04.2009, p. 622-631.

Research output: Contribution to journalArticle

Cruciani, RA, Dvorkin, E, Homel, P, Culliney, B, Malamud, S, Lapin, J, Portenoy, RK & Esteban-Cruciani, N 2009, 'L-Carnitine Supplementation in Patients with Advanced Cancer and Carnitine Deficiency: A Double-Blind, Placebo-Controlled Study', Journal of Pain and Symptom Management, vol. 37, no. 4, pp. 622-631. https://doi.org/10.1016/j.jpainsymman.2008.03.021
Cruciani, Ricardo A. ; Dvorkin, Ella ; Homel, Peter ; Culliney, Bruce ; Malamud, Stephen ; Lapin, Jeanne ; Portenoy, Russell K. ; Esteban-Cruciani, Nora. / L-Carnitine Supplementation in Patients with Advanced Cancer and Carnitine Deficiency : A Double-Blind, Placebo-Controlled Study. In: Journal of Pain and Symptom Management. 2009 ; Vol. 37, No. 4. pp. 622-631.
@article{38fa38377f874364875d79faad6a74c8,
title = "L-Carnitine Supplementation in Patients with Advanced Cancer and Carnitine Deficiency: A Double-Blind, Placebo-Controlled Study",
abstract = "Carnitine deficiency is prevalent in populations with chronic illness, including cancer. In a recent open-label study, L-carnitine supplementation was well tolerated and appeared to improve fatigue and other outcomes in cancer patients. To further evaluate this finding, adult patients with advanced cancer, carnitine deficiency (free carnitine more than 35 μmol/L for males or less than 25 μmol/L for females, or acyl/free carnitine ratio of more than 0.4), moderate to severe fatigue, and a Karnofsky Performance Status (KPS) score of 50 or more, were randomly assigned to receive either L-carnitine (0.5 g/day for two days, followed by 1 g/day for two days, and then 2 g/day for 10 days) or placebo. This double-blind phase was followed by an open-label phase, during which all patients received L-carnitine supplementation for two weeks. Outcomes included the fatigue subscale of the Functional Assessment of Cancer Therapy-Anemia (FACT-An), the Linear Analog Scale Assessments (LASA), the Mini-Mental State Exam (MMSE), and the KPS. Twenty-nine patients (12 placebo, 17 L-carnitine) were included in the intent-to-treat (ITT) analysis. From baseline to the end of the double-blind phase, serum total and free L-carnitine increased from 32.9 ± 3.8 to 56.6 ± 20.5 (P = 0.004), and from 22.9 ± 19.4 to 45.3 ± 17.2 (P = 0.004), respectively, in the L-carnitine-treated group, and from 28.2 ± 10.2 to 36.2 ± 8.7 (P = ns), and from 22.6 ± 7.9 to 28.7 ± 8.6 (P = ns) in the placebo group, respectively. The planned ITT analysis revealed no significant improvement in any of the study's endpoints, and these negative findings were not different when data from two patients who did not adhere to the protocol were eliminated. However, an exploratory covariate analysis that excluded these two protocol violators and included outcome data from both the double-blind and open-label phases demonstrated significantly improved fatigue on the FACT-An fatigue subscale (P < 0.03), and significantly improved FACT-An functional well-being subscale (P < 0.03), and KPS (P < 0.003), in the group that started with L-carnitine during the double-blind phase. These data do not support the conclusion that L-carnitine in the doses tested reverses cancer-related fatigue in carnitine-deficient patients. However, L-carnitine supplementation does increase L-carnitine serum levels, and the positive findings in an exploratory analysis justify a larger study to determine if this strategy could be of benefit for a subpopulation of cancer patients.",
keywords = "advanced cancer, carnitine deficiency, L-Carnitine, supplementation",
author = "Cruciani, {Ricardo A.} and Ella Dvorkin and Peter Homel and Bruce Culliney and Stephen Malamud and Jeanne Lapin and Portenoy, {Russell K.} and Nora Esteban-Cruciani",
year = "2009",
month = "4",
doi = "10.1016/j.jpainsymman.2008.03.021",
language = "English (US)",
volume = "37",
pages = "622--631",
journal = "Journal of Pain and Symptom Management",
issn = "0885-3924",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - L-Carnitine Supplementation in Patients with Advanced Cancer and Carnitine Deficiency

T2 - A Double-Blind, Placebo-Controlled Study

AU - Cruciani, Ricardo A.

AU - Dvorkin, Ella

AU - Homel, Peter

AU - Culliney, Bruce

AU - Malamud, Stephen

AU - Lapin, Jeanne

AU - Portenoy, Russell K.

AU - Esteban-Cruciani, Nora

PY - 2009/4

Y1 - 2009/4

N2 - Carnitine deficiency is prevalent in populations with chronic illness, including cancer. In a recent open-label study, L-carnitine supplementation was well tolerated and appeared to improve fatigue and other outcomes in cancer patients. To further evaluate this finding, adult patients with advanced cancer, carnitine deficiency (free carnitine more than 35 μmol/L for males or less than 25 μmol/L for females, or acyl/free carnitine ratio of more than 0.4), moderate to severe fatigue, and a Karnofsky Performance Status (KPS) score of 50 or more, were randomly assigned to receive either L-carnitine (0.5 g/day for two days, followed by 1 g/day for two days, and then 2 g/day for 10 days) or placebo. This double-blind phase was followed by an open-label phase, during which all patients received L-carnitine supplementation for two weeks. Outcomes included the fatigue subscale of the Functional Assessment of Cancer Therapy-Anemia (FACT-An), the Linear Analog Scale Assessments (LASA), the Mini-Mental State Exam (MMSE), and the KPS. Twenty-nine patients (12 placebo, 17 L-carnitine) were included in the intent-to-treat (ITT) analysis. From baseline to the end of the double-blind phase, serum total and free L-carnitine increased from 32.9 ± 3.8 to 56.6 ± 20.5 (P = 0.004), and from 22.9 ± 19.4 to 45.3 ± 17.2 (P = 0.004), respectively, in the L-carnitine-treated group, and from 28.2 ± 10.2 to 36.2 ± 8.7 (P = ns), and from 22.6 ± 7.9 to 28.7 ± 8.6 (P = ns) in the placebo group, respectively. The planned ITT analysis revealed no significant improvement in any of the study's endpoints, and these negative findings were not different when data from two patients who did not adhere to the protocol were eliminated. However, an exploratory covariate analysis that excluded these two protocol violators and included outcome data from both the double-blind and open-label phases demonstrated significantly improved fatigue on the FACT-An fatigue subscale (P < 0.03), and significantly improved FACT-An functional well-being subscale (P < 0.03), and KPS (P < 0.003), in the group that started with L-carnitine during the double-blind phase. These data do not support the conclusion that L-carnitine in the doses tested reverses cancer-related fatigue in carnitine-deficient patients. However, L-carnitine supplementation does increase L-carnitine serum levels, and the positive findings in an exploratory analysis justify a larger study to determine if this strategy could be of benefit for a subpopulation of cancer patients.

AB - Carnitine deficiency is prevalent in populations with chronic illness, including cancer. In a recent open-label study, L-carnitine supplementation was well tolerated and appeared to improve fatigue and other outcomes in cancer patients. To further evaluate this finding, adult patients with advanced cancer, carnitine deficiency (free carnitine more than 35 μmol/L for males or less than 25 μmol/L for females, or acyl/free carnitine ratio of more than 0.4), moderate to severe fatigue, and a Karnofsky Performance Status (KPS) score of 50 or more, were randomly assigned to receive either L-carnitine (0.5 g/day for two days, followed by 1 g/day for two days, and then 2 g/day for 10 days) or placebo. This double-blind phase was followed by an open-label phase, during which all patients received L-carnitine supplementation for two weeks. Outcomes included the fatigue subscale of the Functional Assessment of Cancer Therapy-Anemia (FACT-An), the Linear Analog Scale Assessments (LASA), the Mini-Mental State Exam (MMSE), and the KPS. Twenty-nine patients (12 placebo, 17 L-carnitine) were included in the intent-to-treat (ITT) analysis. From baseline to the end of the double-blind phase, serum total and free L-carnitine increased from 32.9 ± 3.8 to 56.6 ± 20.5 (P = 0.004), and from 22.9 ± 19.4 to 45.3 ± 17.2 (P = 0.004), respectively, in the L-carnitine-treated group, and from 28.2 ± 10.2 to 36.2 ± 8.7 (P = ns), and from 22.6 ± 7.9 to 28.7 ± 8.6 (P = ns) in the placebo group, respectively. The planned ITT analysis revealed no significant improvement in any of the study's endpoints, and these negative findings were not different when data from two patients who did not adhere to the protocol were eliminated. However, an exploratory covariate analysis that excluded these two protocol violators and included outcome data from both the double-blind and open-label phases demonstrated significantly improved fatigue on the FACT-An fatigue subscale (P < 0.03), and significantly improved FACT-An functional well-being subscale (P < 0.03), and KPS (P < 0.003), in the group that started with L-carnitine during the double-blind phase. These data do not support the conclusion that L-carnitine in the doses tested reverses cancer-related fatigue in carnitine-deficient patients. However, L-carnitine supplementation does increase L-carnitine serum levels, and the positive findings in an exploratory analysis justify a larger study to determine if this strategy could be of benefit for a subpopulation of cancer patients.

KW - advanced cancer

KW - carnitine deficiency

KW - L-Carnitine

KW - supplementation

UR - http://www.scopus.com/inward/record.url?scp=63249123941&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63249123941&partnerID=8YFLogxK

U2 - 10.1016/j.jpainsymman.2008.03.021

DO - 10.1016/j.jpainsymman.2008.03.021

M3 - Article

VL - 37

SP - 622

EP - 631

JO - Journal of Pain and Symptom Management

JF - Journal of Pain and Symptom Management

SN - 0885-3924

IS - 4

ER -